Literature DB >> 9789202

Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.

L Franchini1, A Serretti, M Gasperini, E Smeraldi.   

Abstract

Concordance to antidepressant response in members of the same family is a common observation in clinical practice. However, few published data support this view; moreover families with affected members responder to the same antidepressant have been poorly studied. We have analyzed 45 pairs consisting of one mood disorder fluvoxamine double-responder proband and one first-degree relative with known outcome to fluvoxamine treatment. Among 45 pairs 30 (67%) were concordant for good response to fluvoxamine. In family pedigrees of concordant pairs we found a significantly higher distribution of bipolar forms in secondary cases than in families of non concordant pairs (14.9% vs 3.9% P = 0.039) suggesting that concordance to antidepressant therapy could select families with higher genetic loading.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789202     DOI: 10.1016/S0022-3956(98)00004-1

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  47 in total

Review 1.  The challenges of psychopharmacogenetics.

Authors:  M Catalano
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 2.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Algorithm for the pharmacotherapy of anxiety disorders.

Authors:  Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 4.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

5.  Personalized psychiatry: many questions, fewer answers.

Authors:  Martin Alda
Journal:  J Psychiatry Neurosci       Date:  2013-11       Impact factor: 6.186

6.  Pharmacogenetics of antidepressive treatment.

Authors:  Astrid Zobel; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-01-03       Impact factor: 5.270

7.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

8.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

9.  Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.

Authors:  Firoza Mamdani; Marcelo T Berlim; Marie-Martine Beaulieu; Gustavo Turecki
Journal:  World J Biol Psychiatry       Date:  2013-03-26       Impact factor: 4.132

10.  Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder.

Authors:  Alessandro Serretti; Paola Artioli; Raffaella Zanardi; Cristina Lorenzi; David Rossini; Cristina Cusin; Alessia Arnoldi; Marco Catalano
Journal:  Psychopharmacology (Berl)       Date:  2004-07-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.